Drug Trial Radar · NCT00514306
Study of Intermittent OSI-906 Dosing
Last checked: Nov 19, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
79
Actual
Start
Jul 5, 2007
Primary completion
Sep 20, 2010
Study completion Sep 20, 2010
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Aug 9, 2007
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter, open-label, phase 1, cohort dose escalation study to determine the maximum tolerated dose (MTD) of 3 intermittent OSI-906 dosing schedules.
Conditions
- Advanced Solid Tumors
Interventions
OSI-906Drug
Oral OSI-906 administered on an intermittent schedule at increasing doses until disease progression or unacceptable toxicity
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the maximum tolerated dose (MTD) for each of 3 intermittent schedules and establish a recommended phase 2 dose of OSI-906Time frame: 14 days
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
MD Anderson Cancer Center
Houston, Texas
Drug Development Unit, Royal Marsden Hospital
Sutton, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.